ProtecT Trial 15-Year Follow-Up May be ‘Very Important’ for Prostate Cancer
Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.
Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
Drs Chao and Grunwald review available treatment options as informed by NCCN guidelines for patients with steroid-refractory acute Graft-Versus-Host Disease.
Understanding Acute Graft-Versus-Host Disease
Nelson J. Chao, MD, MBA, and Michael Grunwald, MD introduce acute Graft-Versus-Host Disease (GvHD), sharing how it is diagnosed, how it differs from chronic GvHD, and common signs and symptoms.
Metastatic Renal Cell Carcinoma: Communicating Treatment Options With Patients
Shared insight on the treatment armamentarium for metastatic renal cell carcinoma and how these options should be communicated with patients.
Other Considerations for Better Long-Term Outcomes in Prostate Cancer
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical Scenario 1: Renal Cell Carcinoma Diagnosis and Staging
Centering discussion on a clinical scenario of metastatic renal cell carcinoma, expert panelists reflect on optimal diagnosis and stratification methods in this setting.
The Evolving Landscape of Renal Cell Carcinoma Management
Healthcare professionals reflect on recent evolutions in the renal cell carcinoma treatment landscape.
Support Networks for Patients With Renal Cell Carcinoma
Panelists share their perspective on establishing a support network for patients undergoing treatment for renal cell carcinoma.
177Lu May Be a ‘Good Choice’ for Pretreated Metastatic Prostate Cancer
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM
Shaji Kumar, MD, presents data from an updated analysis of the MAIA trial investigating daratumumab/lenalidomide/dexamethasone for transplant-ineligible NDMM.
Comparing Quadruplet Combination Treatment Regimens in NDMM
The panel compares data between the three presented quadruplet combination regimens for NDMM, and which they would consider for older, frail patients.
Ongoing Trials Suggest Benefits of Radium-223 Combos in Prostate Cancer
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
Bispecific Antibodies Under Investigation in Multiple Myeloma
Noa Biran, MD, offers insights on ongoing research with bispecific antibodies in multiple myeloma.
MM Therapies: Bispecific Antibodies and T-Cell Engagers
A comprehensive discussion on bispecific antibodies and T-cell engagers in the treatment of multiple myeloma.
Monitoring and Educating Patients With GVHD
Experts on graft-vs-host disease discuss patient monitoring and education, and a patient details his experience with GVHD.
Presentations of Acute and Chronic GVHD
A panel of GVHD experts give a comprehensive overview of the presentations of acute and chronic graft-vs-host disease.
Niraparib Shows Favorable Outcomes in Germline BRCA+ Recurrent Ovarian Cancer
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
Ovarian Cancer Palliative Care May Decrease Readmission Rates, Expert Says
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Minimally Invasive Surgery and Laparotomy Yield Similar OS in Ovarian Cancer
Minimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.
Ongoing Radioligand Trials May ‘Shift the Paradigm’ in Prostate Cancer
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
